Crash Estrogen: Yin Biyaya na Farko Menopause
Kowace shekara dubban mata a tsakanin shekarun 15 zuwa 44 suna fama da "Crash Estrogen", kwatsam a cikin matakan estrogen wanda ya bar mata cikin jigilar farkon mazauni. Kodayake ana ganin cewa mazaunawa suna da matsala a cikin mata tsofaffi, yawancin mata da yawa da suka fara yin mata da maza suna ganin kansu ba su da shiri don canje-canjen da ba su faru ba.
Crash Estrogen yana faruwa a yayin da aka cire mace biyu daga ovaries ko a dakatar da aiki a kwatsam. Lokacin da wannan ya faru jikin ya dakatar da samar da estrogen .
"Yawanci, matan mazaopausal suna da karuwa a cikin karuwar estrogen a tsawon shekaru biyu zuwa goma.Mabanin haka, samfurin estrogène na ƙananan mata waɗanda suka sha wahala ga mazajensu ko kuma rashin cin ganyayyaki na mace ko namiji sun mutu ne," in ji Dokta Lila Nachtigall, MD, Darakta na Sashen Harkokin Kiwon Lafiyar Mata a Makarantar Kasuwancin Jami'ar New York. "Sakamakon shine saukowa da gaggawa na bayyanar cututtuka na vasomotor: walƙiya mai zafi, bugu na dare , damuwa da barci mai haɗari da rashin bushewa."
Fiye da miliyoyin mata suna karuwa a kowace shekara a Amurka kuma dan kadan fiye da rabi na hysterectomies sun haɗa da sassan biyu - kawar da ovaries. Fiye da kashi 20 cikin dari na matan da ke fama da juna biyu suna da shekaru 40. Game da daya cikin 100 mata za su ci gaba da cin gajiyar mata a gaban shekaru 40.
Menopause vs. Camarar Cizon
Mata da ke fama da jima'i ba tare da jimawa ba sau da yawa suna jin damuwar mata da yawa da mata da ke da kwarewa a cikin tsufa. A cikin sakaciyar jiki, nauyin estrogen sun ƙi hankali a kan tsawon lokaci daga 2 zuwa 10, yayin da mata masu mazaopausal sun hadu da sauƙi a cikin estrogen.
"Gaba ɗaya, wata mace da ke yin tawaye ta jiki ba za ta fuskanci alamun bayyanar cutar ba" kamar yadda Dr. Lila Nachtigall ya ce. "Yana da matukar ci gaba, mai haƙuri zai iya samun wata daya mara kyau a nan ko kuma a can, amma a yanayin yanayin da ke tsakanin bangarori daban-daban, ƙwayoyin suna da mawuyacin gaske kuma marasa lafiya, musamman, na iya fuskantar halayen haɗari."
A cikin Dokar Nachtigall, kashi 100 cikin dari na mata masu mata masu mata suna da ciwon sukari da kuma kashi 90 cikin 100 na waɗannan mata sun kamu da cututtuka da suka kamu da shekaru 8.5. Ya bambanta, yayinda yawancin 85% na mata mazaopausal na al'ada suna fama da hasken zafi, kawai kimanin 15% na shawo kan cututtuka. A lokacin da mata ke kaiwa mazaunin na halitta, kimanin kashi 43 cikin dari na jigilar cutar da zazzagewa a cikin shekaru 2.
Mata wadanda ke fama da kwatsam bayan kwatsam na rashin lafiya suna fama da rashin lafiya nan da nan bayan an tilasta su haɗiye kwayoyi. Sau da dama likitoci sun rubuta lakaran estrogen wanda aka sa a kan fata kuma ya ba da isrogen ta fata zuwa cikin jini a tsawon kwanakin. Amfanin gashin isrogen shine lokacin bayarda shi.
Mafi ƙanƙancin waɗannan alamun shine Vivelle-Dot. Yanayin .05 mg / day shine girman adadin takarda da kimanin 75% mafi ƙanƙanta fiye da nau'in isrogen.
Ana sawa a ƙananan ƙwayar inda yake bada isradiol ta hanyar suturar fata a cikin jini. Estradiol ita ce asirin na farko wanda ovaries suka samar. Ana sauya Vivelle-Dot sau biyu a mako-mako kuma yana cike da ruwan sama, iyo, da kuma sauran ayyukan yau da kullum ba tare da ya sauka ba. Kullun yana ba da taimako daga walƙiya mai zafi, da gogewa na dare, da sauran alamun bayyanar Crash ta Estrogen ko na mazauni.
Vivelle-Dot yana samuwa a cikin wasu ƙarfin sifofin guda uku; .0375, .075, da .1 MG / rana. Yawancin labaran da suka shafi lalacewa sune ciwon ciwon kai da ƙananan fuska. Abubuwa masu ban mamaki da ke faruwa tare da Vivelle (R) * (tsarin watsa labarai watauradioradio) da placebo, sun hada da ciwon kai (36% vs. 30%), taushi mai tausayi (4.9% vs 1.1%), da kuma riƙewar ruwa (3.8% vs.2.2%).
Wasu marasa lafiya da ke ɗauke da Vivelle-Dot (TM) 0.0375 MG / rana zasu iya shawo kan lokacin da ya dace.
Wasu mata kada su yi amfani da estrogens. Wannan ya hada da matan da aka sani ko ake da ciki, rashin zubar da jini na jini, ciwon daji, neoplasia masu dogara da estrogène, maganin da ke ciki na cutar da cutar, ko tarihin tarihin wadannan yanayi. An bayar da rahoto cewa Estrogens ya kara yawan hadarin carcinoma endometrial a cikin 'yan mata postmenopausal.
W. Neil Jones, Babban Daraktan Daraktan Kasuwanci da Sayarwa na Noven Pharmaceuticals, Inc. ya ce kafofin yada labaru da kulawa da lafiyar ya kamata su taimaki mata mata su fahimci sakamakon da Crash Crash zai haifar don su iya yin shawara mai kyau idan sun sami kansu suna fuskantar farkon mazaopause.
Vivelle-Dot (TM) ne ke kasuwanci ta Novogyne Pharmaceuticals, haɗin gwiwa tsakanin kamfanin Novartis Pharmaceuticals na East Hanover, New Jersey, da Noven Pharmaceuticals, Inc. na Miami, Florida.
* Tsarin asali (Vivelle) (R) da aka gwada a gwajin gwaji ya sake nazari don rage girman nau'in fasalin da kuma tsarin da aka sake nazarin (Vivelle-Dot) (TM) aka nuna shi ya zama daidai ga tsarin asali.
Bayanan bayani: PRNewswire / NEWSdesk